Comparative Pharmacology
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus VIGADRONE.
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant